Searchable abstracts of presentations at key conferences in endocrinology

ea0015p55 | Clinical practice/governance and case reports | SFEBES2008

Cushing’s syndrome or is it? a case report

Christodoulides Constantinos , Walker Neil , Vincent Alex , Karavitaki Niki , Wass John

A 62-year-old lady was referred to our Department with a nine-month history of facial swelling, easy bruising, and centripetal weight gain. She had a longstanding history of depression, hypertension, and osteoarthritis. She was taking citalopram, buspirone, atenolol and bendrofluazide. A few months earlier she had received bilateral intra-articular knee injections at her local hospital for arthritic pain. On examination she had thin skin with multiple bruises, facial puffiness...

ea0013p339 | Thyroid | SFEBES2007

Weekly thyroxine administration: a safe method to administer thyroxine when compliance issues arise

Walker Jonathan , Vincent Alex , Karvitaki Niki , Allahabadia Amit , Weetman Anthony , Wass John

We have studied 20 patients with autoimmune hypothyroidism on large doses of daily thyroxine that were referred to our departments with concerns regarding possible thyroxine malabsorption or compliance issues. Here we describe 3 patients seen in Oxford. One patient had coeliac disease. The other two patients had no history of malaborption and were coeliac antibody negative. None of the 3 patients were on medication which would interfere with thyroxine absorption. All were fema...

ea0059p142 | Neuroendocrinology and pituitary | SFEBES2018

A single-centre audit of treatment outcomes in 185 acromegaly patients under regular follow-up

Muhammad Shoaib Khan Sardar , Mola Laura , Perez-Fernandez Leticia , Vincent Alex , Grossman Ashley , Cudlip Simon , Jafar-Mohammadi Bahram , Pal Aparna

Transsphenoidal adenomectomy (TSA) is the recommended primary therapy in most patients with acromegaly and results in remission for majority of microadenomas and a proportion of macroadenomas depending on extent of surgically accessible disease. Acromegaly is associated with significant mortality and morbidity, hence a combination of treatment modalities may be needed to achieve disease control.Methods: A retrospective casenotes review was conducted and ...

ea0065p285 | Neuroendocrinology | SFEBES2019

The argument for growth hormone day curve testing in acromegaly; significant discrepancy between mean growth hormone and random growth hormone levels

Healy Ultan , Kahn Shoaib , Vincent Alex , Martinez Jacinto , May Christine J H , Wass John , Shine Brian , Jafar-Mohammadi Bahram , Pal Aparna

Endocrine Society guidelines recommend random growth hormone (RGH) <1 mcg/l as indicative of biochemical control of acromegaly. Growth hormone (GH) control may also be determined using the mean GH (MGH) of a growth hormone day curve (GHDC). We report a retrospective analysis of 461 consecutive GHDCs, from 121 patients with treated acromegaly, performed in a single centre between 2009 and 2019. Each GHDC contained 7–9 GH measurements (mean 8.9) taken at regular interva...